Where Will Lifecore Biomed Be in 5 Years? CEO Shares Insights
Can a 60-year-old sterile injectable pioneer double margins within five years?
CEO Paul Josephs details Lifecore Biomed’s three-pronged plan to win in the CDMO race.
• Lifecore’s new filler and doubled capacity for big-pharma clients
• Pipeline outlook: 11 late-stage launches slated for 2026-2029
• From “farming” to “hunting” — a revamped sales approach
• Financial targets: 12% revenue CAGR and EBITDA topping 25%
• New leadership, culture of ownership, and early AI pilots
• Macro tailwinds: reshoring, site transfers, and CDMO demand
————————————————————————
This video is brought to you by The Motley Fool.
Visit https://fool.com/Invest to get access to this special offer. The Motley Fool Stock Advisor returns are 1,069% as of 8/27/2025 and measured against the S&P 500 returns of 185% as of 8/27/2025. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well.
————————————————————————
